Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06351020Phase 3Active Not Recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Role: lead

NCT05161390Phase 1Completed

Study of LM-302 in Patients With Advance Solid Tumors

Role: lead

NCT05934331Phase 2Recruiting

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Role: lead

All 3 trials loaded